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Background: High-dose, pharmacological ascorbate (P-AscH−) is preferentially cytotoxic to human cancer 
cells in vitro. Investigations on the efficacy of P-AscH− as an adjuvant treatment for multiple human 
cancers are on-going, but has yet to be formally investigated in dogs. The primary objectives of this study 
were to determine the pharmacokinetic (PK) profile of P-AscH− in healthy Beagle dogs and the effects of 
P-AscH− on canine osteosarcoma cells in vitro. 
Methods: Eight purpose-bred, healthy, spayed female Beagle dogs, between 20 and 21 months old, and 
8–10 kg were administered two doses of P-AscH− (550 or 2,200 mg/kg) via intravenous infusion over 6 h, 
on separate days. Plasma ascorbate concentrations were measured at 12 time points during and after 
infusion for PK analysis using nonlinear mixed-effects (NLME) and non-compartmental analysis (NCA). 
Clonogenic assays were performed on 2 canine osteosarcoma cell lines (D-17 and OSCA-8) and canine 
primary dermal fibroblasts after exposure to high concentrations of ascorbate (75 pmoles/cell). 
Results: Plasma ascorbate levels in the dogs peaked at approximately 10 mM following 2,200 mg/kg and 
returned to baseline 6–8 h after dosing. Minor adverse effects were seen in two dogs. Ascorbate (75 
pmoles/cell) significantly decreased survival in both the osteosarcoma cell lines (D-17 63% SD 0.010, P = 
0.005; OSCA-8 50% SD 0.086, P = 0.026), compared to normal fibroblasts (27% SD 0.056). 
Conclusions: Pharmacological ascorbate is preferentially cytotoxic to canine-derived cancer cells. High 
levels of ascorbate can be safely administered to dogs. Further studies are needed to determine the 
effects of P-AscH− on canine patients. 
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Background: High-dose, pharmacological ascorbate (P-AscH−) is preferentially
cytotoxic to human cancer cells in vitro. Investigations on the efficacy of P-AscH− as
an adjuvant treatment for multiple human cancers are on-going, but has yet to be
formally investigated in dogs. The primary objectives of this study were to determine
the pharmacokinetic (PK) profile of P-AscH− in healthy Beagle dogs and the effects of
P-AscH− on canine osteosarcoma cells in vitro.
Methods: Eight purpose-bred, healthy, spayed female Beagle dogs, between 20 and 21
months old, and 8–10 kg were administered two doses of P-AscH− (550 or 2,200 mg/kg)
via intravenous infusion over 6 h, on separate days. Plasma ascorbate concentrations
were measured at 12 time points during and after infusion for PK analysis using nonlinear
mixed-effects (NLME) and non-compartmental analysis (NCA). Clonogenic assays were
performed on 2 canine osteosarcoma cell lines (D-17 and OSCA-8) and canine primary
dermal fibroblasts after exposure to high concentrations of ascorbate (75 pmoles/cell).
Results: Plasma ascorbate levels in the dogs peaked at approximately 10mM following
2,200 mg/kg and returned to baseline 6–8 h after dosing. Minor adverse effects were
seen in two dogs. Ascorbate (75 pmoles/cell) significantly decreased survival in both
the osteosarcoma cell lines (D-17 63% SD 0.010, P = 0.005; OSCA-8 50% SD 0.086,
P = 0.026), compared to normal fibroblasts (27% SD 0.056).
Conclusions: Pharmacological ascorbate is preferentially cytotoxic to canine-derived
cancer cells. High levels of ascorbate can be safely administered to dogs. Further studies
are needed to determine the effects of P-AscH− on canine patients.
Keywords: canine, vitamin C, high-dose, osteosarcoma, intravenous
INTRODUCTION
The potential benefit of high-dose intravenous (IV) pharmacological ascorbate (P-AscH−, vitamin
C) for patients with cancer was first reported in the 1970s (1, 2). Subsequent clinical trials failed
to show substantial improvement in outcome (3), stalling its clinical use (4). However, P-AscH−
continued to be a popular alternative cancer therapy (5, 6). The potential anti-cancer properties of
P-AscH− are being reevaluated. Several human clinical trials are examining the efficacy and safety
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of P-AscH−, for example in non-small cell lung carcinoma
(NSCLC) (7), glioblastoma multiforme (GBM) (7), and
pancreatic cancer (8, 9), indicating renewed interest in the
therapeutic use of P-AscH− for human cancer patients.
Ascorbic acid is a weak acid with pKa1 of about 4.2 (8).
Thus, at the near-neutral pH of mammalian biology, greater
than 99.9% will be present as the monoanion, i.e., ascorbate.
The biochemistry for the functions of vitamin C is principally
the biochemistry of ascorbate. In this work, we use the
term pharmacolocial ascorbate, P-AscH−, to distinquish the
functioning of ascorbate as a drug from its biochemistry as
vitamin C (10, 11). When at normal, healthy physiologic levels
ascorbate functions as a reducing agent and donor antioxidant
(12); however, at supraphysiological concentrations, P-AscH−
can produce high fluxes of H2O2 via its oxidation (8, 9, 13).
The cytotoxic mechanism of P-AscH− appears to be due to these
fluxes of H2O2 and, in part, to alterations in cancer cell oxidative
metabolism, allowing for increased steady-state levels of O•−2 and
H2O2 within tumor cells (7, 14, 15). These alterations disrupt
intracellular iron metabolism, sensitizing cells to the effects of
the oxidation of P-AscH− (7, 14, 15). Multiple in vitro studies
have confirmed the cytotoxic effects of P-AscH− on human
and murine tumor cells, and the sparing effect on normal cells
(10, 11, 14, 15).
Human studies of P-AscH− have determined that therapeutic,
cytotoxic plasma levels (≥≈20mM) cannot be achieved through
oral administration (PO) (16). Therefore, IV or intraperitoneal
(IP) injection is required (16, 17). In addition, high-dose IV P-
AscH− infusions (15–125 g), given over hours, are required to
achieve and maintain proposed therapeutic plasma levels due to
the rapid clearance of ascorbate (7, 16–19). The optimal dose of
P-AscH−, frequency, and duration of administration have yet to
be determined (20).
Pharmacological ascorbate is generally well-tolerated and
appears to have no dose-limiting toxicities in humans (6).
Adverse effects that have been described include vomiting,
diarrhea, weight loss, leukopenia, and neutropenia (6, 7, 10, 21).
Canine pharmacokinetic (PK) analysis of PO ascorbate,
but not P-AscH−, has been scientifically evaluated (22). In 4
Greyhounds that were treated with 1 g of ascorbate PO or IV,
peak ascorbate plasma concentrations were significantly greater
when ascorbate was administered IV (mean 0.33 ± 0.06mM)
compared to PO (mean 0.03 ± 0.01mM) and was achieved
within 6min, falling rapidly back to baseline (mean 0.01mM)
within 6 h (23). Recently, seven dogs were reported to have
received various doses of IV ascorbate for the adjuvant treatment
of multiple cancers with minimal side effects (24). Data regarding
the PK of P-AscH− in dogs, and if P-AscH− would be a feasible
treatment option for our canine patients, are lacking.
The purpose of this study was two-fold: (1) determine
the PK profile of P-AscH− in healthy Beagle dogs; and (2)
determine the effects of P-AscH− on canine osteosarcoma
cells. Given the lack of significant adverse side effects reported
in humans, we hypothesized that IV P-AscH− would be
safe for use in dogs and that in vitro, P-AscH− would
cause significant cytotoxicity to canine osteosarcoma cells.
The PK data presented here can guide the development of
treatment protocols that are feasible for use in the veterinary
clinical setting.
METHODS
Experimental Animals
Eight purpose-bred, spayed female Beagles, between 20 and 21
months old, and 8–10 kg were used in this study. The dogs were
obtained from Ridglan Farms, Mt. Horeb, WI. The use of the
Beagles for this study was approved by the Iowa State University
Institutional Animal Care and Use Committee. Compliance with
the USNational Research Council’s Guide for the Care and Use of
Laboratory Animals was maintained throughout the study. The
Beagle dogs were group-housed in the same conditions and fed
the same Royal Canin R© diet for the duration of the study. Prior
to infusions of P-AscH− and collection of blood samples, dogs
were fasted overnight with free choice water available at all times.
Ascorbate Administration
Two doses of injectable L-ascorbic acid, 500 mg/mL (Mylan
Institutional LLC, Canonsburg, PA), were administered on two
separate days. (Although labeled as Ascorbic Acid for Injection,
the contents are at near-neutral pH, thus vials contain ascorbate.)
A low dose (550 mg/kg) was administered on the first trial day.
This dose was escalated to 2,200 mg/kg for administration on the
second trial day, as previously reported (24). At least a two-day
washout period was given between each dose. Administration
of ascorbate was performed through a 20 gauge, peripheral
short IV catheter in the left or right cephalic vein of each dog.
Pharmacological ascorbate was combined with sterile water to
achieve a 500mg ascorbate per mL solution with a targeted
osmolarity between 500 and 900 mOsm/L (7). The infusion was
given over 6 h (12.5 mL/h for the 550 mg/kg dose; 50 mL/h
for the 2,200 mg/kg dose) via an IV infusion pump in order to
achieve a steady-state plasma ascorbate concentration. Dogs were
continuously monitored during the infusion and intermittently
for 24 h post infusion for adverse clinical signs.
Plasma Ascorbate Sample Preparation and
Analysis
To evaluate plasma ascorbate concentrations throughout and
after infusion, blood was sampled at 12 time points: immediately
prior to the ascorbate infusion, a baseline venous sample was
obtained; venous blood was sampled at 0.5, 1, 3, 5, and 6 h
during the infusion period; and at 6.5, 7, 8, 10, 12, and 16 h
during the post-infusion period. Prior to the higher dose infusion
(2,200 mg/kg), and at the 6 h mark of the higher dose infusion,
arterial samples for blood gas analysis were also obtained. All
venous blood collection was performed via a Cavafix R© (B Braun
Medical Inc., Breinigsville, PA) sampling catheter placed in
either the left or right lateral saphenous vein, to the level of
the caudal vena cava, following manufacturer recommendations
(25). At each time point, 2mL whole blood samples were drawn
into a Vacutainer R© PSTTM Lithium Heparin (Becton Dickinson,
Franklin Lakes, NJ) green top tube and promptly stored on ice
until centrifugation. Blood was centrifuged for 20min at 4◦C
and 2,000 rpm (671 g). Plasma was collected and stored at
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−80◦C until analysis (26). Arterial samples for blood gas analysis
were obtained via an AirLifeTM Reduced Heparin Arterial Blood
Sampler (CareFusion).
Plasma ascorbate quantification was conducted at The
University of Iowa using two different assay systems as previously
described (27, 28). Briefly, a plate reader (SpectraMax R© M3,
Molecular Devices, Sunnyvale, CA) was used to measure baseline
and physiological levels of ascorbate present in the plasma
samples (28). To quantify the high pharmacological levels of
ascorbate a second assay using an Implen Nanophotometer
(Implen GmbH, Munich, Germany) microvolume UV-Vis
spectrometer was used. With little required sample processing,
this assay, developed at The University of Iowa (27), allows rapid
assessment of ascorbate concentrations in plasma ranging from
2.9 to 35 mM.
Arterial blood gas samples were processed by the Iowa State
University Clinical Pathology Lab using a RAPIDPoint R© 500
Blood Gas Analyzer (Siemens Medical Solutions USA, Inc.,
Malvern, PA). Additional complete blood counts, chemistries,
and urinalyses were performed in conjunction with another study
taking place during the same time period.
Pharmacokinetic Modeling
Time-courses for the concentration of ascorbate in blood plasma
following low-dose and high-dose IV infusion were analyzed
simultaneously using the stochastic approximation expectation
maximization (SAEM) algorithm implemented in the Monolix
Suite 2018R2 (Lixoft, France). Data below the lower limit
of quantification (LLOQ) were modeled by adding to the
likelihood function a term describing the probability that the
true observation lies between zero and the LLOQ. Individual
model parameters were obtained post-hoc using the mean of
the full posterior distribution, as previously described for non-
linear mixed-effects (NLME) models in animal health (29).
Convergence of the SAEM algorithmwas evaluated by inspection
of the stability of the fixed and random effect parameter search
and the log-likelihood estimate after the exploratory period of
the algorithm (i.e., after 1,000 iterations of SAEM). Standard
goodness-of-fit diagnostics, including individual predictions
vs. observations, the distributions of weighted residuals, and
normalized prediction distribution errors were used to assess
the performances of the candidate models (30–32). Prediction
distributions from 1,000 Monte Carlo simulations were used
to evaluate the ability of the final model to reproduce the
variability in the observed pharmacokinetic data. Residual
error estimates from the mathematical models were used as
supportive information for evaluation of lack of fit. Normality
and independence of residuals were assessed using histograms,
quantile-quantile plots, and autocorrelation of conditional
weighted residuals. For converging models with satisfactory
goodness-of-fit diagnostics, model selection was based on the
Bayesian information criteria (BIC) and the precision of the
model parameter estimates.
For completeness, non-compartmental analysis (NCA) of
ascorbate PK was performed using PKanalix (Monolix Suite
2019R1, Lixoft, France). Standard PK parameters were generated
for individual dogs, as follows:
• Area under concentration-time curve, AUC INF;
◦ A linear trapezoidal linear rule was used to estimate the area
under the ascorbate time-curves
• Maximum concentration, CMAX;
• Steady state concentration, CSS;
• Steady state volume, VSS;
• Clearance, Cl;
• Time of maximum concentration, TMAX;
• Half-life, T1/2;
• Elimination rate constant, λz;
◦ Computed by linear regression of the logarithmic
concentration vs. time curve during the elimination phase
In vitro Ascorbate Analysis—Cell Lines and
Reagents
Two canine osteosarcoma cell lines were obtained, D-17
(American Type Culture Collection, Rockville, MD, USA) and
OSCA-8 (Kerafast, Inc., Boston, MA), and grown in pyruvate
free DMEM 10% fetal bovine serum (FBS). Canine primary
dermal fibroblasts were obtained as a normal tissue control (Cell
Biologics, Chicago, IL). Cell lines were grown in proprietor
complete fibroblast media (M2267 for dermal fibroblasts)
containing 1mM pyruvate. Cells were kept in either 21 or 4% O2
at 37◦C, 5% CO2, in a humidified atmosphere.
For cell culture studies, ascorbate stock solutions, 1M inwater,
with the pH adjusted to 7.0 with NaOH were prepared from
L-ascorbic acid (Macron Fine Chemicals, Avantor Performance
Materials, Inc., Center Valley, PA) and stored in the dark at
5◦C in sealed glass test tubes until use (11). The ascorbate stock
concentration was verified spectrophotometrically. Appropriate
volumes of the stock to achieve 50 pmole/cell (5mM) and 75
pmol/cell (7.5mM) were added to culture media for 1 h as
previously described (7, 11).
In vitro Ascorbate Analysis—Clonogenic
Survival Assay
To determine the effect of P-AscH− on the reproductive integrity,
D-17 and OSCA-8 canine osteosarcoma cells were plated at
80,000 cells per 60-mm dish. Seventy-two hours after plating,
one dish was counted to determine the number of cells on the
plate. The volume of media in the dishes was adjusted so that
cells were treated with a range of stock ascorbate, 2.5 pmoles/cell
(0.25mM)−50 pmoles/cell (5mM). Ascorbate was dosed per cell
as previous literature has demonstrated that H2O2 and ascorbate
toxicity depends on cell number/density (15, 33, 34). After 1 h of
P-AscH− treatment both floating and attached cells from control
and treated dishes were collected using 0.25% trypsin (GIBCO).
Trypsin was inactivated with media containing any floating cells,
centrifuged at 1,200 rpm (335 g) for 5min and resuspended
in fresh media. Cell counts were made with a Coulter Counter
(Beckman Coulter Z1) and the cells were plated at various
densities and allowed to grow for 10–12 days in complete media
at 21% O2. Subsequently, the cells were stained with Coomassie
Blue dye, and colonies of >50 cells on each plate were counted
and recorded. Surviving fraction was determined as the number
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of colonies per plate divided by the number of cells initially added
to that plate. Normalized surviving fraction was determined
as the surviving fraction of any given clonogenic plate from a
treatment group divided by the average surviving fraction of the
control (untreated) plates within a given experiment.
The clonogenic experiment comparing osteosarcoma cells
to canine fibroblast cells were performed similarly with the
following exceptions. Optimal conditions for normal fibroblasts
is 4% O2 (normal physiologic condition) and proprietary media
(complete fibroblast media M2267) which contains sodium
pyruvate, known to scavenge H2O2 (15). In addition, normal
canine fibroblasts will only form clones when plated on lethally
irradiated feeder cells (see below). Therefore, in experiments
comparing the reproductive viability of P-AscH− on cancer cells
vs. fibroblasts, the dose of P-AscH− was increased to 75 pmol/cell
(7.5mM) and all cultures, including the sarcoma lines, were
treated in identical fibroblast media at 4% O2 and plated onto
feeder cells.
In vitro Ascorbate Analysis—B1 Feeder
Layer Cells
Chinese hamster fibroblasts designated as B1 (passages 20–
40) were maintained at 21% oxygen in high glucose DMEM
1× media containing L-glutamine and sodium pyruvate and
supplemented with 10% FBS, 20 mmol/L HEPES, pH 7.3, 1×
MEM non-essential amino acids. The feeder layer was prepared
24 h prior to any clonogenic survival assay by irradiating the cells
with 30Gy of X-rays at a dose rate of 27 Gy/min then plating
in the cloning dishes at 100,000 cells per dish. During clonogenic
survival assays comparing P-AscH− treatment of cancer cell lines
to normal canine fibroblasts, all cloning plates were grown using a
feeder layer and each clonogenic experiment had two extra dishes
plated with feeder cells alone to ensure no colony growth at the
end of the 10- to 12-day incubation.
Statistical Analysis
The clonogenic survival analysis was done using a minimum
of three cloning dishes per experimental condition, and the
experiments were repeated aminimum of three times on separate
occasions. Statistical analyses were done using the GraphPad
Prism software. Statistical significance was determined using
one-way ANOVA and Dunnett’s multiple comparisons test was
performed. Error bars represent ± standard error of the mean,
and statistical significance was defined as P < 0.05.
The Wilcoxon signed rank test was used to examine the
difference between the pre- and post-ascorbate administration
for each of nine safety parameters evaluated by blood gas. A P-
value < 0.05 was considered significant. Statistical analysis was
performed using R (version 3.5.2) (R Foundation for Statistical
Computing, Vienna, Austria).
RESULTS
Safety
The ascorbate infusion was well-tolerated by all dogs, with one
dog experiencing a grade I veterinary cooperative oncology
group-common terminology criteria for adverse events (VCOG-
CTCAE) vomiting during the higher dose infusion, and another
showing VCOG-CTCAE grade I nausea/ptyalism (35). No
changes on complete blood count or chemistry panels were
noted during the course of the study for any dog. Blood gas
analysis revealed statistically significant changes in pre- and post-
ascorbate calcium, sodium, potassium, chloride, bicarbonate,
partial pressure of carbon dioxide, anion gap, lactate, and glucose
measurements (Table 1). The pH was not significantly different
pre- and post-ascorbate administration.
In vivo Pharmacokinetics
The mean initial plasma ascorbate concentration for the eight
dogs at the 550 mg/kg P-AscH− dose (≈4 g) was 0.02mM (±
TABLE 1 | Arterial blood gas and electrolyte abnormalities observed in eight Beagle dogs after receiving pharmacological ascorbate (2,200 mg/kg).
Parameter Median
pre-ascorbate
Median
post-ascorbatea
Median
difference
(post - pre)
IQR
differenceb
P-valuec Canine normald Ascorbate and sterile
water blank
Ca (mmol/L) 1.37 1.40 0.030 0.030 0.034 1.23–1.40 Decreased out of range
Na (mmol/L) 146 152 6.00 4.25 0.007 143–151 224x
K (mmol/L) 3.56 3.39 -0.170 0.170 0.015 3.60–4.70 <1
Cl (mmol/L) 114 107 -7.00 1.50 0.013 109–117 N/A
HCO3 (mmol/L) 21.3 22.7 1.40 0.900 0.015 19.0–25.0 N/A
pCO2 (mmHg) 37.1 39.9 2.80 3.15 0.023 29.0–45.0 N/A
Anion gap
(mmol/L)
15.6 28.4 12.8 4.10 0.007 12.0–21.0 N/A
Lactate (mmol/L) 0.64 8.64 8.00 2.10 0.007 0.43–2.10 Increased out of range
Glucose (mg/dL) 107 51.5 -55.5 23.0 0.014 62.0–115 246
pH 7.37 7.37 0.00 0.040 1.00 7.34–7.45 N/A
aBlood was drawn at the 6-h mark immediately following cessation of pharmacological ascorbate infusion.
b IQR: interquartile range.
cP-values for differences were obtained from the Wilcoxon signed-rank test (significance level = 0.05).
dCanine Normal displays a generally accepted normal range for healthy dogs for each parameter for the RAPIDPoint 500 analyzer (36, 37).
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0.01mM). Over the course of the 6-h infusion, this peaked
to 2.14mM (± 0.54mM). Once the infusion was completed,
ascorbate levels fell sharply below therapeutic levels, and returned
to near baseline by 6 h post infusion (Figure 1). The mean initial
plasma ascorbate concentration for the eight dogs at the 2,200
mg/kg dose of P-AscH− (≈15–21 g) was 0.02mM (± 0.01mM).
Over the course of the 6-h infusion, this peaked to 8.6± 2.1mM.
Once the infusion was completed, ascorbate levels fell sharply
below proposed therapeutic levels, and returned to near baseline
by 6 h post infusion (Figure 1).
A two-compartment mammillary disposition model with
first-order elimination and zero-order absorption following IV
infusion best described the PK of ascorbate in plasma (Figure 2).
A combined error model with an additive and a proportional
error term was used to account for the residual noise in ascorbate
measurement. The robustness and predictive performances of the
final model were supported by the inspection of the standard
goodness-of-fit diagnostics (Supplemental Figure 1). Overall,
the model was able to reproduce the individual experimental data
for the two dosing schedules with excellent accuracy, as shown by
the quality of the individual fits (Figure 3).
Using standard mathematical equations for a two-
compartment PK model (38), the elimination half-life of
ascorbate in canine plasma can be estimated at ∼3.5 h.
Population PK parameter estimates and their related variances
are summarized in Table 2. For all model parameters, the
precision of the final estimates was considered satisfactory
(RSE ≤ 25%). The systemic total body clearance (CL) of
ascorbate was estimated to be low to moderate (2.0 L/h, or
0.24 L/kg/h), according to previous definition (39), while the
steady-state volume of distribution was estimated to be relatively
small (2.69 L or 0.32 L/kg), with the central compartment
occupying most of the distribution of ascorbate in dogs.
The global extraction ratio of ascorbate (E) calculated as
CL/Q [with cardiac output Q (mL/kg/min)] approximated by
the formula: Q = 180 × BW−0.19(39), was estimated to be
low (E= 0.03).
Prediction distributions (from the 2.5th to 97.5th percentile)
derived from 1,000 Monte Carlo simulations confirmed the good
performances of the final selected model which was able to
reproduce the variability in the observed disposition kinetic data
of circulating ascorbate following IV infusion dosing (Figure 4).
The NCA PK parameters are collated in Table 3. The mean
maximum ascorbate plasma concentration was estimated as 9.23
± 1.33mM for beagles administered 2,200 mg/kg P-AscH− and
2.26 ± 0.61mM for beagles administered 550 mg/kg P-AscH−.
Peak plasma concentrations were observed around a median
value of 5.5 ± 1.0 h. Mean clearance and steady state volume
estimates were unremarkable (2.05 ± 0.35 L/h and 3.52 ± 1.54 L
FIGURE 2 | Schematic pharmacokinetic representation of the
two-compartment model developed in this study. Ascorbate was administered
intravenously (I.V.) with an infusion time denoted by tinf. The transfer between
the two compartments is governed by intercompartmental transfer parameter
Q, and the drug’s elimination was determined by the clearance from the
central compartment (CL).
FIGURE 1 | In vivo pharmacokinetics of two doses of pharmacological ascorbate in eight healthy Beagle dogs. Distribution of individual ascorbate concentrations
(small open circles) are plotted alongside the mean ascorbate concentrations (dashed line) and standard error (bars) for all observations at each time point following
ascorbate infusions (550 and 2,200 mg/kg).
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FIGURE 3 | Individual predicted concentration of ascorbate in plasma. Individual predicted curves (blue) are plotted against the individual measurements of ascorbate
(gray circles) over time. There are two individual fits for each animal dependent on dose. The difference between the individual predictions and observations defines
the residual error in the model, which is low in these cases.
TABLE 2 | Model parameter pharmacokinetic estimates as determined by the
stochastic approximation expectation-maximization algorithm.
Parameter Symbol Unit Point estimate RSE (%) IIV (%)
Clearance CL L/h 2.04 3.18 6.86
Central Volume V1 L 1.96 5.99 11.9
Inter-compartmental Clearance Q L/h 0.16 15.0 –
Peripheral Volume V2 L 0.76 24.7 46.6
RSE, Relative Standard Error of the Estimate; IIV, Inter-individual Variability.
respectively). The median elimination half-life was estimated at
3.73 ± 1.47 h. All NCA PK parameters agree well with their
NLME counterparts.
Clonogenic Assay
To test the hypothesis that treatment with P-AscH− decreases
clonogenic survival in canine osteosarcoma cancer cells, D-
17 and OSCA-8 were treated with 0.25–50 pmol/cell ascorbate
for 1 h. In both cell lines, P-AscH− treatment resulted in
significant (P < 0.001), dose-dependent decreases in clonogenic
cell survival compared to untreated controls (Figure 5A). To test
the hypothesis that P-AscH− causes differential susceptibility in
osteosarcoma cells vs. normal canine dermal fibroblast, again
clonogenic survival assay was performed. Optimal growing
conditions for dermal fibroblast include proprietary media
containing 1 mmol pyruvate and 4% O2. Both O2 and pyruvate
have been demonstrated to affect the production and removal
of H2O2 with ascorbate treatment (15), therefore clonogenic
assay was done using 75 pmol/cell P-AscH− for 1 h and optimal
fibroblast growing conditions for both the cancer cell lines and
normal fibroblast cells. Treatment with P-AscH− demonstrated
significant differential susceptibility in osteosarcoma cells vs.
normal fibroblast by decreasing clonogenic survival in both
osteosarcoma cell lines (D-17 63%, SD= 0.010, P= 0.005; OSCA-
8 50%, SD = 0.086, P = 0.026), more than normal fibroblasts
(27%, SD= 0.056) (Figure 5B).
Frontiers in Veterinary Science | www.frontiersin.org 6 November 2019 | Volume 6 | Article 385
Musser et al. Pharmacological Ascorbate in Dogs
FIGURE 4 | Prediction of ascorbate distribution. These figures were produced by Monte Carlo simulation from the model fit. Briefly, a population of 2,000 individuals
were simulated. Half were virtually administered a dose equal to 2,200 mg/kg and the other half were administered a dose equal to 550 mg/kg. Then, at each time
point from 0 to 16 h in steps of 0.05 h, i.e., (0, 0.05, 0.1, 0.15, …,15.95, 16), the quantiles of the resulting simulations were calculated and plotted along with
observations for comparison (gray dots).
TABLE 3 | Non-compartmental analysis pharmacokinetic parameters.
Mean PK parameters ± SD Median PK parameters ± SD
Group AUCINF CMAX CSS VSS Cl λz TMAX T1/2
Unit mM*h mM mM L L/h 1/h h h
All 33.7 ± 22.4 5.74 ± 3.73 5.37 ± 3.74 3.52 ± 1.54 2.05 ± 0.35 0.22 ± 0.12 5.5 ± 1.0 3.73 ± 1.47
2,200 mg/kg 54.5 ± 8.8 9.23 ± 1.33 9.01 ± 1.47 2.60 ± 0.51 1.96 ± 0.16 0.25 ± 0.13 6.00 ± 1.36 3.87 ± 1.44
550 mg/kg 12.8 ± 3.1 2.26 ± 0.61 2.06 ± 0.51 4.44 ± 1.52 2.15 ± 0.46 0.18 ± 0.08 5.00 ± 0.52 3.73 ± 1.49
SD, standard deviation; AUCINF , median area under curve; CMAX , maximum concentration; CSS, steady state concentration; VSS, steady state volume; Cl, clearance; TMAX , time of
maximum concentration; T1/2, half-life; λz , elimination rate constant.
DISCUSSION
Based on the plasma ascorbate concentration analysis reported
herein, it has been determined that it is safe to administer P-
AscH− (2,200 mg/kg) to healthy dogs. Using an infusion rate of
50 mL/h of a solution containing 500mg ascorbate per mL, in
vivo peak plasma ascorbate concentrations reached up to 10mM
and were found to be dose-dependent. To our knowledge, this is
the first comprehensive characterization of ascorbate PK in dogs.
A two-compartmental mammillary disposition model with first-
order elimination and zero-order absorption after IV infusion
dosing best described the available PK data. Parameter estimates
of the final NLME model suggest that ascorbate has a rather
low extraction ratio (0.03) but a small volume of distribution,
resulting in a short elimination half-life in dogs, in agreement
with previous findings from the human literature (19).
Adverse effects that were previously noted in human studies,
including vomiting, diarrhea, and weight loss, were minimal in
our canine subjects (21). During the infusion of both doses,
and for at least 24 h post infusion, only one dog vomited. All
dogs remained bright, alert, and responsive, had a good appetite
following the infusion, and maintained their body condition.
This suggests that P-AscH− will be well-tolerated in healthy dogs,
even at elevated doses.
It is worth noting that in the present study, mild changes on
blood gas analysis were noted after administration of 2,200mg/kg
P-AscH− (Table 1). There are several possible explanations for
these findings, the first of which is analytical interference. A
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FIGURE 5 | Pharmacological ascorbate treatment results in selective clonogenic cell death in canine osteosarcoma cell lines. (A) Significant dose dependent
decreases in clonogenic survival for two osteosarcoma cell lines (D-17 and OSCA-8) following treatment with 0.25–50 pmol/cell ascorbate at 21% O2 DMEM no
pyruvate 10% FBS media. (B) Significant survival differences between two osteosarcoma cell lines (D-17 and OSCA-8) vs. primary canine fibroblasts after treatment
with 75 pmol/cell ascorbate in fibroblast media 4% O2. *Denotes statistical significance.
significant elevation in anion gap and hyperlactatemia were
observed 6 h into the infusion of the higher dose P-AscH−
(2,200 mg/kg) in all eight dogs. Ascorbic acid has been shown
to interfere with blood gas electrodes that use oxidase for
amperometric methods of detection (namely lactate and glucose)
(40, 41), including the Siemens analyzer used in this study
(42). Additionally, when a comparable solution of ascorbate and
sterile water was run alone, elevations in lactate were detected
(Table 1), suggesting the apparent hyperlactatemia is most likely
due to an electrode analytical interference and may not be
clinically relevant.
Alternatively, hyperlactatemia is a reported side effect
of multiple drugs, the mechanism of which is varied but
does include interference with the Cori cycle, inhibition
of mitochondrial protein synthesis, inhibition of the
electron transport chain (ETC), and uncoupling of oxidative
phosphorylation (43). Recent research with P-AscH− in humans
revealed that several of the mitochondrial ETC complexes
may be inhibited during treatment (7), possibly contributing
to the hyperlactatemia. The true cause of the hyperlactaemia
in the Beagles is unknown, and may be a combination of
analytical interference and more insidious causes. Awareness
of this possible elevation is extremely important as use of
ascorbate becomes prevalent in clinically ill dogs and humans.
Future studies are needed to determine if hyperlactatemia
is truly due to analytical interference or if it might be more
clinically relevant.
Elevated bicarbonate and hypernatremia were noted and
expected, as the formulation of P-AscH− is buffered by sodium
and bicarbonate. Expected compensatory hypochloremia and
high pCO2 were also observed. The elevation of sodium and
decreased chloride may also be attributed to analytical inference,
as erroneous hypernatremia and hypochloremia have been noted
previously following the use of P-AscH− (40). Glucose, although
expected to be high (44), was found to be decreased in all 8
Beagles. This was attributed to the fast prior to and during the
infusion of P-AscH−.
Hypokalemia was likely due to increased diffusion of ascorbate
into cells, followed by secondary increase in Na/K-ATPase
activity and rapid intracellular potassium uptake (dogs synthesize
ascorbate from glucose via the glucuronic pathway and absorb
it via passive diffusion, while in people ascorbate requires
facilitated diffusion or active transport) (45, 46). This is contrary
to an expected hyperkalemia that has been noted in humans
and has been attributed to an analytical interference (40). This
discrepancy may be attributed to the different mechanisms by
which ascorbate is taken into cells in dogs compared to humans.
Calcium at the upper end of the reference interval post-
treatment was an unexpected finding, as in people ascorbate acts
as a weak calcium chelator, possibly leading to hypocalcemia (47).
However, ascorbate has been shown to interfere with calcium
analysis, much like lactate, usually resulting in false elevations
(40), which may have occurred in our study. In addition, high
doses of oral ascorbate have previously been found to cause
hypercalcemia in broiler chickens and hens, likely due to altered
calciummetabolism (either enhancement of intestinal absorption
or resorption of bone) (48), which may be a phenomenon unique
to species that can synthesize ascorbate, such as dogs.
Most of the blood gas analysis changes, although
mathematically significant, were considered to be mild
and are likely due to analytical interference caused by high
concentrations of ascorbate in the plasma. Knowledge of these
possible alterations, however, are important so that overzealous
correction of these temporary, and likely clinically insignificant,
changes does not occur to the detriment of the patient. Further
analysis is necessary to make conclusions about the causes of
these observed changes.
The two assays for the determination of plasma ascorbate
concentrations used in this study have not previously been
reported in a canine trial setting. The plate reader assay has
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been validated with canine, porcine and human plasma (28). The
0 h results (≈20µM) from this study fall within the established
detection range for the assay and correspond with values that
were found in the validation study (28). To date, the Implen
Nanophotometer has not been used to quantify plasma ascorbate
in canines (49). A recent study confirmed the ability to use
UV spectroscopy to rapidly quantify high concentrations (up to
35mM) of human plasma ascorbate, with minimal processing
(27). Using this same assay on our canine plasma samples
detected ascorbate concentrations that corresponded with those
found in human and murine studies (7, 17, 21). The novel use
of these quantification methods in this study provides proof of
concept for future studies.
In vitro, following treatment with P-AscH− ranging from
0.25 to 50 pmole/cell, the clonogenic cell survival of both
OSA cell lines (D-17 and OSCA-8) was significantly decreased
compared to untreated controls in a dose-dependent manner
(Figure 5A). Similarly, the clonogenic survival of both cell lines
after treatment with 75 pmole/cell (7.5mM) of P-AscH− was
significantly decreased compared to normal canine fibroblasts
(Figure 5B). This is similar to human OSA in vitro studies, which
showed a dose-dependent decrease in cell growth following
exposure to P-AscH− (range of doses up to 1mM) and a sparing
of normal control cells; the most significant growth effects were
found at the 1mM concentration (50, 51). Similar findings have
been confirmed for a variety of human tumors (7). Recently,
the in vitro effects of P-AscH− on canine melanoma cell lines
have also been investigated, and show similar, dose-dependent
findings with IC50 values (those that reduce the survival of each
cell line by 50%) between 3.6 and 9.9 mM (52).
Utilizing human cell lines, ascorbate concentrations of
1–7mM are required for cytotoxicity and additional cell kill is
achieved with higher doses (10). However, the suggested target
level of plasma ascorbate that is believed to be most effective
for humans is ≈20mM (7). When the Beagles received a dose
of 2,200 mg/kg over 6 h, plasma levels peaked at approximately
10mM around the 6 h mark. Although this is above the in vitro
cytotoxic threshold of 7.5mM, it is below the target dose in
humans. However, it is not known if the human target level of
20mM is required, or if lower plasma concentrations may be
equally successful. In addition, in vitro data cannot be directly
correlated with an expected cytotoxic dose in vivo, as conditions
in these two situations are different (15). Specifically, for in vitro
P-AscH− treatment, the cell cultures contain 1mM of pyruvate
which is known to remove cytotoxic H2O2, potentially interfering
with the main mechanism of action of P-AscH−, and decreasing
the observed effects of P-AscH− in vitro (53).
The level of intracellular labile iron also influences the
cytotoxicity of P-AscH− (7, 14). In general, normal cells have a
lower labile iron pool compared to cancerous cells, potentially
explaining the sparing effects of P-AscH− on normal cells. The
level of labile iron in the OSA cells is unknown, but it is possible
that they have a relatively decreased amount of iron, impacting
the cytotoxicity of P-AscH− in vitro. Similarly, this would impact
cytotoxic levels in vivo should a particular patient have a tumor
with inherently less labile iron, be anemic (54), have endogenous
or exogenous exposure to glucocorticoids (55), or have circadian
drops in iron (56), complicating administration and assessment
of an expected cytotoxic dose. In vivo tumor analysis of P-AscH−
levels are required to fully assess the concentrations of P-AscH−
achievable and if these levels are clinically effective.
In vitro analysis also fails to replicate the in vivo
microenvironment that exerts a significant influence on the
achievable intracellular levels of therapeutics. Thus, direct
correlations between the cytotoxic in vitro dose of P-AscH− and
that which will be cytotoxic in vivo is not possible. The in vitro
information can guide in vivo experiments and the interpretation
of results. Our in vitro data suggest that P-AscH− is cytotoxic to
canine OSA cell lines, providing proof of concept for additional
investigations in tumor-bearing dogs.
Interestingly, it has been determined that pancreatic cancer,
NSCLC, and GBM cells treated with ascorbate are more sensitive
to concurrent or subsequent treatment with ionizing radiation
and chemotherapy, while normal cells were spared (7, 57).
In a murine model, it has been shown that pharmacologic
ascorbate enhances pancreatic tumor cell radiation cytotoxicity
while offering potential protection from radiation damage to
normal surrounding tissue (57). This indicates that adjuvant
ascorbate combined with other cancer therapies, may be
more advantageous than ascorbate alone, or that synergism
between treatments may imply a lower dose of P-AscH−
would still be effective (58). Further research into this area
is needed to determine the best use of ascorbate in our
canine patients.
The most advantageous dosing strategy for P-AscH− is
also unknown (20). Recent literature report that the clearance
of P-AscH− in humans following a 60-g dose was 6.0 L/h
(19). In light of this fast elimination from the body, a bolus
loading dose followed by a maintenance infusion of P-AscH−
was recommended to maintain P-AscH− concentrations in the
potential cytotoxic range (>20mM) (19), but this dosing was not
studied further. In the current Beagle study, a clearance of 2.0 L/h
was identified. This slower clearance may indicate that an in vivo
cytotoxic dose is achievable in dogs.
This study evaluated the use of P-AscH− in healthy
Beagle dogs. It is acknowledged that oncology patients
may have significantly different plasma dispositions of P-
AscH− due to their disease that may influence dosing,
PK parameters, toxicity, and efficacy of this treatment in
the clinical setting. Clinical patients will be of a variety of
breeds, who may process P-AscH− differently from Beagles
due to genetic differences. In addition, clinical patients will
be on a variety of medications, including chemotherapy,
which may cause unintended drug-drug interactions, or
alter the PK parameters, toxicity, and efficacy of P-AscH−.
Additional studies in tumor-bearing dogs are needed to fully
evaluate the PK parameters and impact of P-AscH− in canine
oncology patients.
In summary, the findings presented here give a biological
basis for the efficacy of ascorbate in vitro and an understanding
of the pharmacokinetics of P-AscH− in healthy dogs. Together,
they provide compelling evidence to investigate the concurrent
use of ascorbate with standard of care chemotherapy and
radiation therapy in tumor-bearing dogs. The combined in
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vitro and in vivo results suggest that P-AscH− may be a
safe, reasonable adjuvant therapeutic option for dogs diagnosed
with cancer, specifically osteosarcoma, and that cytotoxic doses
of ascorbate may be achievable in vivo. Further studies
are necessary to determine the optimal dose to achieve
cytotoxic levels in tumor tissue, ideal dosing strategies, and
to confirm the safety profile when combined with traditional
oncologic therapies.
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